New Findings from Hannover Medical School Describe Advances in Type 2 Diabetes (Trends of Antidiabetic and Cardiovascular Diseases Medication Prescriptions in Type 2 Diabetes between 2005 and 2017-A German Longitudinal Study Based on Claims Data): Nutritional and Metabolic Diseases and Conditions – Type 2 Diabetes

2023 MAR 24 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Current study results on type 2 diabetes have been published. According to news reporting out of Hannover, Germany, by NewsRx editors, research stated, “With an attempt to understand possible mechanisms behind the severity-dependent development of type 2 diabetes (T2D) comorbidities, this study examines the trends of antidiabetic and cardiovascular diseases (CVD) medication prescriptions in individuals with T2D. The study is based on claims data from a statutory health insurance provider in Lower Saxony, Germany.”

Financial supporters for this research include Ministry For Science And Culture of Lower Saxony; German Research Foundation; Aok-lower Saxony.

Our news reporters obtained a quote from the research from Hannover Medical School: “The period prevalence of antidiabetic and CVD medication prescriptions was examined for the periods 2005-2007, 2010-2012, and 2015-2017 in 240,241, 295,868, and 308,134 individuals with T2D, respectively. (Ordered) logistic regression analyses were applied to examine the effect of time period on the number and prevalence of prescribed medications. Analyses were stratified by gender and three age groups. The number of prescribed medications per person has increased significantly for all examined subgroups. For the two younger age groups, insulin prescriptions decreased but those of non-insulin medications increased, while both increased significantly over time for the age group of 65+ years. Except for glycosides and antiarrhythmic medications, the predicted probabilities for CVD medications increased over the examined periods, with lipid-lowering agents demonstrating the highest increase.”

According to the news editors, the research concluded: “Results point towards an increase in medication prescriptions in T2D, which is in line with the evidence of the increase in most comorbidities indicating morbidity expansion. The increase in CVD medication prescriptions, especially lipid-lowering agents, could explain the specific development of severe and less severe T2D comorbidities observed in this population.”

For more information on this research see: Trends of Antidiabetic and Cardiovascular Diseases Medication Prescriptions in Type 2 Diabetes between 2005 and 2017-A German Longitudinal Study Based on Claims Data. International Journal of Environmental Research and Public Health, 2023,20(4491):4491. (International Journal of Environmental Research and Public Health - http://www.mdpi.com/journal/ijerph). The publisher for International Journal of Environmental Research and Public Health is MDPI AG.

A free version of this journal article is available at https://doi.org/10.3390/ijerph20054491.

Our news journalists report that more information may be obtained by contacting Batoul Safieddine, Medical Sociology Unit, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. Additional authors for this research include Florian Trachte, Stefanie Sperlich, Jelena Epping, Karin Lange, Siegfried Geyer.

(Our reports deliver fact-based news of research and discoveries from around the world.)